Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Summary

Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of acute kidney rejection only. There is no clinical data of its use in heart transplant patients.

Timeline

Start

2006-06

Primary completion

2009-12

Completion

2009-12

Drugs

Indications

No indication recorded.